Vonoprazan not checked
FollowEvery change as it happens, and a Monday email
Trials
2 active
14 in total
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants with non-erosive gastroesophageal reflux disease (GERD).”In the company’s words, NCT07752407 on ClinicalTrials.gov
Other drugs for Symptomatic Non-erosive Gastroesophageal Reflux Disease
- JP-1366Onconic Therapeutics Inc. · Phase 3
- Linaprazan GlurateCinclus Pharma Holding AB · Phase 1
- TrimedatValenta Pharm JSC · Phase 1
- AD-120Addpharma Inc. · Phase 1
- TegoprazanHK inno.N · Marketed (Phase 4 trial)
- TegoprazanCarnot Laboratories · Marketed (Phase 4 trial)
Coming up1
- 20 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials14
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 20 Oct 2027 | A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks | |
| Phase 2Active, not recruiting | 11 Sep 2026 | A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks | |
| Phase 3Completed | 10 Mar 2021 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection | |
| Phase 3Completed | 29 Jul 2021 | Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis | |
| Phase 3Completed | 21 Nov 2022 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo for Relief of Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) | |
| Phase 2Completed | 16 Dec 2021 | A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease | |
| Phase 1Completed | 13 Nov 2020 | Evaluation of Effect of Vonoprazan on Midazolam Pharmacokinetics in Healthy Participants | |
| Phase 1Withdrawn | 7 Feb 2021 | Evaluation of Effect of Rifampin on the Pharmacokinetics of Vonoprazan in Healthy Participants | |
| Phase 1Completed | 12 Jun 2021 | Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants | |
| Phase 1Completed | 1 Jul 2022 | A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants | |
| Phase 1Completed | 30 May 2023 | A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Vonoprazan in Adolescents With Symptomatic Gastroesophageal Reflux Disease | |
| Phase 1Completed | 16 Apr 2024 | A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease | |
| Phase 1Completed | 13 Sep 2024 | A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily | |
| Phase 1Completed | 5 Apr 2025 | A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026